Good evening, this is Markets Desk with your closing look at what's moving markets and the broader economy.
The Federal Reserve is front and center tonight, as Wall Street recalibrates its rate expectations. New Fed Chair Kevin Warsh is reading as less hawkish than many anticipated, and with inflation cooling more than headline numbers suggest, the wave of rate hikes markets had been bracing for may simply never arrive. Sectors sensitive to borrowing costs are quietly positioning for that outcome.
Shifting to individual names, AbbVie touched a fresh fifty-two week high today, raising the inevitable question of whether the pharmaceutical giant has run too far too fast. The answer, at least by traditional valuation metrics, appears to be no. The stock has outpaced the broader market this year, yet its multiple remains comparatively modest, which keeps the bull case intact for patient investors.
And in the AI hardware space, Cerebras Systems continues to face pressure after a strong run. The company carries an elevated valuation, and any deceleration in growth from here would be difficult for the stock to absorb. The question over the next three years is whether its revenue trajectory can grow into that price tag before sentiment turns.
That's the tape. Markets Desk, signing off the floor.
